TORONTO, ONTARIO--(Marketwired - Dec. 14, 2016) - Spectral Medical Inc. ("Spectral" or the "Company")
(TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with endotoxemic septic shock
using a medical device, today announced that after a detailed review of the trading volume, costs and administrative requirements
related to maintaining the Company's listing on the OTCQX, it has voluntarily delisted its Common shares from the OTCQX effective
January 1, 2017. Spectral's Common shares will continue to be listed on the Toronto Stock Exchange.
About Spectral Medical Inc.
Spectral is a Phase III company seeking U.S. FDA approval for its unique product Toraymyxin™ ("PMX") for the treatment of
patients with septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the
bloodstream and is directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of
developing sepsis.
PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000
patients to date. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year.
Currently there is no specific treatment available for this condition.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit www.spectraldx.com.
Forward-looking Statement
Information in this news release that is not current or historical factual information may constitute forward-looking
information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of
Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation,
they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties,
including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to commercialize its products, the ability of Spectral to take advantage of business
opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general
economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.